European Journal of Cancer
Volume 39, Issue 6 , Pages 742-747 , April 2003

An EORTC-ECSG phase I study of LU 79553 administered every 21 or 42 days in patients with solid tumours

  • A Awada

      Affiliations

    • Jules Bordet Institute, Bd de Waterloo 125, 1000 Brussels, Belgium
    • Corresponding Author InformationCorresponding author. Tel.: +32-2-541-3219; fax: +32-2-538-0858
    • ,
  • R Thödtmann

      Affiliations

    • III. Medizinische Klinik, München, Germany
    • ,
  • M.J Piccart

      Affiliations

    • Jules Bordet Institute, Bd de Waterloo 125, 1000 Brussels, Belgium
    • ,
  • J Wanders

      Affiliations

    • New Drug Development Office, Free University Hospital, PO Box 7057, 1007 MB Amsterdam, The Netherlands
    • ,
  • A.H.G.J Schrijvers

      Affiliations

    • New Drug Development Office, Free University Hospital, PO Box 7057, 1007 MB Amsterdam, The Netherlands
    • ,
  • I.-M Von Broen

      Affiliations

    • Knoll AG, Knollstrasse, 67061 Ludwigshafen, Germany
    • ,
  • A.R Hanauske

      Affiliations

    • AK St. Georg, Division of Medical Oncology, I. Dept of Medicine, Lohmühlenstrasse 5, 20099 Hamburg, Germany

Received 17 October 2002 ,Accepted 28 October 2002.

References 

  1. Brana MF, Castellano JM, Roldan CM, Santos A, Vazquez D, Jiminez A. Synthesis and mode of action of a new series of imide derivatives of 3-nitro 1,8-naphthalic acid. Cancer Chemother. Pharmacol. 1980;4:61–68
  2. Brana MF, Castellano JM, Sanz AM, Roldan CM, Roldan C. Synthesis and cytostatic activity of benz [3, e]isoquinolin-1,3-diones (structure-activity relationships). Eur. J. Med. Chem. 1981;16:207–212
  3. Brana MF, Castellano JM, Moran M, et al.  Bisnaphthalimides (a new class of antitumor agents). Anticancer Drugs Des. 1993;8:257–268
  4. Waring MJ, Gonzalez A, Jiminez A, Vazquez D. Intercalative binding to DNA of antitumor drugs derived from 3-nitro-1,8-naphthalic acid. Nucleic Acids Res. 1979;7:212–230
  5. Bousquet PF, Brana MF, Colon D, et al.  Preclinical evaluation of LU 79553, a novel bisnaphthalimide with potent antitumor activity. Cancer Res. 1995;55:1176–1180

PII: S0959-8049(02)00776-1

doi: 10.1016/S0959-8049(02)00776-1

European Journal of Cancer
Volume 39, Issue 6 , Pages 742-747 , April 2003

Article Tools

* Image Usage & Resolution